A prospective study of adjuvant CMF in males with node positive breast cancer: 20-Year follow-up

Janice M. Walshe, Arlene W. Berman, Ujala Vatas, Seth M. Steinberg, William F. Anderson, Marc E Lippman, Sandra M. Swain

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalBreast Cancer Research and Treatment
Volume103
Issue number2
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Methotrexate
Fluorouracil
Cyclophosphamide
Prospective Studies
Breast Neoplasms
Male Breast Neoplasms
Adjuvant Chemotherapy
Survival
Neoplasms
National Cancer Institute (U.S.)
Mastectomy
Progesterone Receptors
Estrogen Receptors
Lymph Nodes
Drug Therapy

Keywords

  • Adjuvant chemotherapy
  • CMF chemotherapy
  • Male breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Walshe, J. M., Berman, A. W., Vatas, U., Steinberg, S. M., Anderson, W. F., Lippman, M. E., & Swain, S. M. (2007). A prospective study of adjuvant CMF in males with node positive breast cancer: 20-Year follow-up. Breast Cancer Research and Treatment, 103(2), 177-183. https://doi.org/10.1007/s10549-006-9363-0

A prospective study of adjuvant CMF in males with node positive breast cancer : 20-Year follow-up. / Walshe, Janice M.; Berman, Arlene W.; Vatas, Ujala; Steinberg, Seth M.; Anderson, William F.; Lippman, Marc E; Swain, Sandra M.

In: Breast Cancer Research and Treatment, Vol. 103, No. 2, 01.06.2007, p. 177-183.

Research output: Contribution to journalArticle

Walshe, JM, Berman, AW, Vatas, U, Steinberg, SM, Anderson, WF, Lippman, ME & Swain, SM 2007, 'A prospective study of adjuvant CMF in males with node positive breast cancer: 20-Year follow-up', Breast Cancer Research and Treatment, vol. 103, no. 2, pp. 177-183. https://doi.org/10.1007/s10549-006-9363-0
Walshe, Janice M. ; Berman, Arlene W. ; Vatas, Ujala ; Steinberg, Seth M. ; Anderson, William F. ; Lippman, Marc E ; Swain, Sandra M. / A prospective study of adjuvant CMF in males with node positive breast cancer : 20-Year follow-up. In: Breast Cancer Research and Treatment. 2007 ; Vol. 103, No. 2. pp. 177-183.
@article{3a1f2e5d83944690aad217eb6e4cc4e7,
title = "A prospective study of adjuvant CMF in males with node positive breast cancer: 20-Year follow-up",
abstract = "Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68{\%}) had 1-3 positive axillary lymph nodes while ten patients (32{\%}) had four or more positive nodes. Estrogen receptor status was positive in 22 (71{\%}), negative in 1 (3{\%}), and unknown in 8 (26{\%}) tumors. Progesterone receptor status was positive in 18 (58{\%}), negative in 3 (10{\%}), and unknown in 10 (32{\%}) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5{\%} (95{\%} CI: 46.9-78.9{\%}), at 15 years is 51.6{\%} (95{\%} CI: 34.8-68{\%}), and at 20 years is 42.4{\%} (95{\%} CI: 25.8-60.8{\%}). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.",
keywords = "Adjuvant chemotherapy, CMF chemotherapy, Male breast cancer",
author = "Walshe, {Janice M.} and Berman, {Arlene W.} and Ujala Vatas and Steinberg, {Seth M.} and Anderson, {William F.} and Lippman, {Marc E} and Swain, {Sandra M.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1007/s10549-006-9363-0",
language = "English",
volume = "103",
pages = "177--183",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - A prospective study of adjuvant CMF in males with node positive breast cancer

T2 - 20-Year follow-up

AU - Walshe, Janice M.

AU - Berman, Arlene W.

AU - Vatas, Ujala

AU - Steinberg, Seth M.

AU - Anderson, William F.

AU - Lippman, Marc E

AU - Swain, Sandra M.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.

AB - Purpose: To determine the long-term overall survival of male patients with stage II node positive breast cancer treated with adjuvant chemotherapy. Patients and methods: Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute. Following mastectomy, patients were treated with 12 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy. Results: Median patient age was 61 years (38-74 years). Twenty-one patients (68%) had 1-3 positive axillary lymph nodes while ten patients (32%) had four or more positive nodes. Estrogen receptor status was positive in 22 (71%), negative in 1 (3%), and unknown in 8 (26%) tumors. Progesterone receptor status was positive in 18 (58%), negative in 3 (10%), and unknown in 10 (32%) tumors. Median potential follow-up for all patients is 22.5 years with a median survival of 16.3 years. Twenty-one of 31 patients have died; one from a treatment-related complication, nine patients from recurrent breast cancer, five from other cancers, one from non-cancer related causes, and five from unknown causes. Ten patients remain alive at a median of 19.2 years. The overall survival probability at 10 years is 64.5% (95% CI: 46.9-78.9%), at 15 years is 51.6% (95% CI: 34.8-68%), and at 20 years is 42.4% (95% CI: 25.8-60.8%). Conclusion: To our knowledge, 20-year prospective data with adjuvant chemotherapy in male breast cancer has never been reported. Adjuvant chemotherapy may benefit male breast cancer patients with positive nodes.

KW - Adjuvant chemotherapy

KW - CMF chemotherapy

KW - Male breast cancer

UR - http://www.scopus.com/inward/record.url?scp=34249053878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249053878&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9363-0

DO - 10.1007/s10549-006-9363-0

M3 - Article

C2 - 17039267

AN - SCOPUS:34249053878

VL - 103

SP - 177

EP - 183

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -